Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 59.5M shares rose 2.0% year over year, in line with the +1.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of +1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.5M+1.4% QoQ
Last fiscal yearDec 2025
58.69M+1.8% YoY
LTMMar 2026
58.91M+1.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year+1.8%——
3-year CAGR+15.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
58.69M USD
Year-over-year change
+1.8%
4-year CAGR
+11.7%

Weighted Avg Shares vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's LTM Mar 2026 weighted avg shares of 58.91M shares is the 6th highest of the 11 companies compared; the peer median is 53.6M shares.
  • Its year-over-year change of +1.6% is the 7th highest of 11, against a peer median of +2.4%.
  • Over three fiscal years its annual growth of +15.2% compares with a peer median of +11.6%.
VYGR Competitors Peer median
Weighted Avg Shares for VYGR and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +5.9%+9.8%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
Peer median (excluding VYGR) 53.6M+2.4%+11.6%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42M40.91M250.01M80M40.37M
Cost of Revenue73.79M55.76M92.17M00
Gross Profit(36.37M)(14.86M)157.84M80M40.37M
Gross Margin-97.2%-36.3%63.1%100.0%100.0%
Research & Development73.79M60.76M92.17M127.37M134.67M
Selling, General & Admin37.25M30.98M35.82M35.92M37.54M
Operating Expenses37.25M35.98M35.82M163.29M172.22M
Depreciation & Amortization5.17M6.19M4.44M4.73M4.06M
EBITDA(66.03M)(39.65M)138.18M(59.61M)(115.52M)
EBITDA Margin-176.5%-96.9%55.3%-74.5%-286.1%
Operating Income(73.62M)(50.84M)122.01M(83.29M)(131.84M)
Operating Margin-196.8%-124.3%48.8%-104.1%-326.6%
Interest Income01.79M11.72M18.33M10.62M
Interest Expense00000
Other Income / Expenses2.42M4.45M11.72M18.95M12.27M
Income Before Tax(71.2M)(46.39M)133.74M(64.34M)(119.58M)
Pre-Tax Margin-190.3%-113.4%53.5%-80.4%-296.2%
Income Tax Expense016K1.41M665K144K
Net Income(71.2M)(46.41M)132.33M(65M)(119.72M)
Net Margin-190.3%-113.4%52.9%-81.3%-296.5%
EPS (Basic)(1.75)(1.21)3.08(1.13)(2.04)
EPS (Diluted)(1.75)(1.21)2.97(1.13)(2.04)
Weighted Avg Shares37.67M38.36M43.02M57.67M58.69M
Weighted Avg Shares (Diluted)37.67M38.36M44.57M57.67M58.69M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.